HIV-1 Tat inhibits neprilysin and elevates amyloid β

Objective:Aging is a risk factor for amyloid beta (Aβ) accumulation and dementia. Since highly active antiretroviral therapies have effectively lengthened the life expectancy of individuals infected with HIV-1, we investigated the affect of HIV-1 Tat, a viral transactivating transcription factor, on Aβ degradation in the brain by neprilysin (NEP), a neuronal endopeptidase. Design and methods:Using neural cell membrane fractions from human brain aggregates, Tat inhibition of NEP activity was assessed in a fluorescence assay. Following treatment with Tat, conditioned medium of human brain aggregate cultures was assayed for Aβ1–40 by ELISA. We evaluated the potential consequence of Tat inhibition of NEP by immunostaining cortex sections from postmortem human brain for Aβ. Results:In an in vitro assay, Tat inhibited NEP activity by 80%. The cysteine-rich domain of Tat was essential for NEP inhibition. Recombinant Tat added directly to brain cultures, resulted in a 125% increase in soluble Aβ. Postmortem human brain sections from patients with HIV-1 infection (n = 14; 31–58 years old) had a significant increase in Aβ, compared to controls (n = 5; 30–52 years old). Correlative analysis identified a statistically significant relationship between Aβ load and duration of HIV-1 seropositive status. Conclusion:We have shown that Tat, which is found in the brains of patients with HIV-1 infection, inhibits the Aβ-degrading enzyme, NEP. Aβ staining was significantly increased in human brain sections from individuals with HIV-1 infection compared to controls. These results have important implications for individuals living and aging with HIV-1 infection.

[1]  D. Selkoe,et al.  The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease , 1998 .

[2]  T. Saido,et al.  Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition , 2000, Nature Medicine.

[3]  M. McGrath,et al.  Human immunodeficiency virus-infected macrophages produce soluble factors that cause histological and neurochemical alterations in cultured human brains. , 1991, The Journal of clinical investigation.

[4]  Lars Lannfelt,et al.  HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy , 1998, Nature Medicine.

[5]  R. Rabin,et al.  HIV-1 Tat protein mimicry of chemokines. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[6]  D. Selkoe.  The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. , 1998, Trends in cell biology.

[7]  M. Staufenbiel,et al.  Extracellular amyloid formation and associated pathology in neural grafts , 2003, Nature Neuroscience.

[8]  Y. Miller,et al.  Neuroendocrine differentiation, neuropeptides, and neprilysin. , 1999, American journal of respiratory cell and molecular biology.

[9]  Andrew P. Rice,et al.  Tat protein of human immunodeficiency virus type 1 is a monomer when expressed in mammalian cells. , 1991, Virology.

[10]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[11]  D. Bredt,et al.  Tat protein from human immunodeficiency virus forms a metal-linked dimer. , 1988, Science.

[12]  T. Saido,et al.  Metabolic Regulation of Brain Aβ by Neprilysin , 2001, Science.

[13]  K. Davis,et al.  Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. , 2000, JAMA.

[14]  M. Ohno,et al.  BACE1 Deficiency Rescues Memory Deficits and Cholinergic Dysfunction in a Mouse Model of Alzheimer's Disease , 2004, Neuron.

[15]  T. Saido,et al.  Metabolic regulation of brain Abeta by neprilysin. , 2001, Science.

[16]  C. Finch,et al.  Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  D. Coates,et al.  The neprilysin (NEP) family of zinc metalloendopeptidases: Genomics and function , 2001, BioEssays : news and reviews in molecular, cellular and developmental biology.

[18]  H. Gendelman,et al.  Human immunodeficiency virus type 1 infection of the nervous system: Pathogenetic mechanisms , 1993, Annals of neurology.

[19]  M. Esiri,et al.  Prevalence of Alzheimer plaques in AIDS , 1998, Journal of neurology, neurosurgery, and psychiatry.

[20]  E. Masliah,et al.  Changes in pathological findings at autopsy in AIDS cases for the last 15 years , 2000, AIDS.

[21]  R. Tanzi,et al.  Uptake of HIV-1 Tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands , 2000, Nature Medicine.

[22]  A. Turner,et al.  Kidney neutral endopeptidase and the hydrolysis of enkephalin by synaptic membranes show similar sensitivity to inhibitors. , 1982, The Biochemical journal.

[23]  B. Berkhout,et al.  Intracellular analysis of in vitro modified HIV Tat protein. , 1994, The Journal of biological chemistry.

[24]  L. K. Baker,et al.  Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability* , 2002, The Journal of Biological Chemistry.

[25]  H. Hamazaki.  Cathepsin D is involved in the clearance of Alzheimer's beta-amyloid protein. , 1996, FEBS letters.

[26]  K. Jellinger,et al.  Neuropathology and general autopsy findings in AIDS during the last 15 years , 2000, Acta Neuropathologica.

[27]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[28]  H. Hamazaki.  Cathepsin D is involved in the clearance of Alzheimer's β‐amyloid protein , 1996 .

[29]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Luigi Buonaguro,et al.  HIV‐1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix‐associated heparan sulfate proteoglycans through its basic region , 1997, AIDS.

[31]  L. Pulliam,et al.  Changes in monocyte/macrophage neurotoxicity in the era of HAART: implications for HIV-associated dementia , 2002, AIDS.

[32]  H. Brodt,et al.  Changing incidence of AIDS‐defining illnesses in the era of antiretroviral combination therapy , 1997, AIDS.

[33]  L. Hudson,et al.  Detection of the human immunodeficiency virus regulatory protein tat in CNS tissues. , 2000, Journal of neurovirology.

[34]  P. Wingfield,et al.  Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation , 1993, Journal of virology.

[35]  L. Hersh,et al.  Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation* , 1998, The Journal of Biological Chemistry.